NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading GRAL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is loss-making, and while it has shown some positive momentum recently, the overall outlook remains uncertain.
The market seems to have priced in a justified valuation, with a low expectations gap. However, GRAL trades at a premium compared to its peers, indicating that investors may be anticipating potential upside.
Management aims for revenue growth of 22-32% in 2026, but recent results show a decline in revenue. The company's financial performance is currently neutral, and there is a low probability of missing earnings, though past performance has been inconsistent.
The future of GRAL depends on sector performance, particularly the results of major players like TMO, DHR, and IDXX. If these companies continue to perform well, it could support GRAL; however, any negative guidance from them could pose risks.
In the next 1 to 3 years, GRAL's prospects will largely depend on its ability to execute on growth targets and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. A legal challenge could impact investor confidence. This adds uncertainty to the company's outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: GRAIL aims for 22-32% revenue growth in 2026. Q2 results will show if they are on track.
Confirms:Q2 revenue growth exceeds 5% compared to Q1's $40.8M.
Disproves:Q2 revenue growth is below 5% compared to Q1.
Why it matters: This report will show GRAIL's financial performance and growth path.
Confirms one read:Earnings report shows revenue growth and positive outlook.
Confirms the other:The earnings report shows lower revenue or negative guidance.
Why it matters: Approval would show the test is safe and effective. This would boost market trust.
Confirms:FDA grants PMA approval for the Galleri test.
Disproves:FDA may reject the PMA application or ask for more data.
Why it matters: Expanding partnerships can drive growth and validate GRAIL's strategy. Stagnation may signal issues.
Confirms:Announcement of at least two new partnerships in digital health.
Disproves:No new partnerships announced in the next quarter.
Why it matters: New leadership can shift company direction. Positive changes may enhance growth prospects.
Confirms one read:The new CEO, Dr. Joshua Ofman, announced good plans for the company.
Confirms the other:The new CEO has not announced any big changes or plans.
Why it matters: Completing this submission is crucial for GRAIL's regulatory progress. Delays could hinder growth.
Confirms:Announcement of PMA submission for Galleri completed by the end of Q3.
Disproves:Further delays in the PMA submission timeline.
Why it matters: Meeting the revenue growth target signals strong demand and execution in the market.
Confirms:Q2 revenue grows between 22% and 32% year over year.
Disproves:Q2 revenue growth falls below 22% year over year.
Why it matters: This integration could help more patients and doctors access the Galleri test.
Confirms:Epic EHR integration will be done and working by the end of 2026.
Disproves:Integration fails to launch by the end of 2026 or faces significant delays.
Why it matters: Good data from these trials could build trust and interest in Galleri.
Confirms one read:Positive results came from the NHS-Galleri trial and PATHFINDER 2 study at ASCO.
Confirms the other:Bad results or no important findings were reported from these studies.
